Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

233 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Amivantamab in EGFR Exon 20 Insertion-Mutated Non-Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study.
Park K, Haura EB, Leighl NB, Mitchell P, Shu CA, Girard N, Viteri S, Han JY, Kim SW, Lee CK, Sabari JK, Spira AI, Yang TY, Kim DW, Lee KH, Sanborn RE, Trigo J, Goto K, Lee JS, Yang JC, Govindan R, Bauml JM, Garrido P, Krebs MG, Reckamp KL, Xie J, Curtin JC, Haddish-Berhane N, Roshak A, Millington D, Lorenzini P, Thayu M, Knoblauch RE, Cho BC. Park K, et al. Among authors: lorenzini p. J Clin Oncol. 2021 Oct 20;39(30):3391-3402. doi: 10.1200/JCO.21.00662. Epub 2021 Aug 2. J Clin Oncol. 2021. PMID: 34339292 Free PMC article. Clinical Trial.
Daratumumab Plus Atezolizumab in Previously Treated Advanced or Metastatic NSCLC: Brief Report on a Randomized, Open-Label, Phase 1b/2 Study (LUC2001 JNJ-54767414).
Pillai RN, Ramalingam SS, Thayu M, Lorenzini P, Alvarez Arias DA, Moy C, Hutnick N, Knoblauch R, Feng H, Kane C, Horn L, Reck M, Ponce S; LUC2001 Investigators. Pillai RN, et al. Among authors: lorenzini p. JTO Clin Res Rep. 2020 Oct 7;2(2):100104. doi: 10.1016/j.jtocrr.2020.100104. eCollection 2021 Feb. JTO Clin Res Rep. 2020. PMID: 34589982 Free PMC article.
Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study.
Park K, Sabari JK, Haura EB, Shu CA, Spira A, Salgia R, Reckamp KL, Sanborn RE, Govindan R, Bauml JM, Curtin JC, Xie J, Roshak A, Lorenzini P, Millington D, Thayu M, Knoblauch RE, Cho BC. Park K, et al. Among authors: lorenzini p. Lung Cancer. 2023 Apr;178:166-171. doi: 10.1016/j.lungcan.2023.02.008. Epub 2023 Feb 15. Lung Cancer. 2023. PMID: 36868177 Free article.
Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial.
Cho BC, Kim DW, Spira AI, Gomez JE, Haura EB, Kim SW, Sanborn RE, Cho EK, Lee KH, Minchom A, Lee JS, Han JY, Nagasaka M, Sabari JK, Ou SI, Lorenzini P, Bauml JM, Curtin JC, Roshak A, Gao G, Xie J, Thayu M, Knoblauch RE, Park K. Cho BC, et al. Among authors: lorenzini p. Nat Med. 2023 Oct;29(10):2577-2585. doi: 10.1038/s41591-023-02554-7. Epub 2023 Sep 14. Nat Med. 2023. PMID: 37710001 Free PMC article. Clinical Trial.
Subcutaneous Versus Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: Primary Results From the Phase III PALOMA-3 Study.
Leighl NB, Akamatsu H, Lim SM, Cheng Y, Minchom AR, Marmarelis ME, Sanborn RE, Chih-Hsin Yang J, Liu B, John T, Massutí B, Spira AI, Lee SH, Wang J, Li J, Liu C, Novello S, Kondo M, Tamiya M, Korbenfeld E, Moskovitz M, Han JY, Alexander M, Joshi R, Felip E, Voon PJ, Danchaivijitr P, Hsu PC, Silva Melo Cruz FJ, Wehler T, Greillier L, Teixeira E, Nguyen D, Sabari JK, Qin A, Kowalski D, Şendur MAN, Xie J, Ghosh D, Alhadab A, Haddish-Berhane N, Clemens PL, Lorenzini P, Verheijen RB, Gamil M, Bauml JM, Baig M, Passaro A; PALOMA-3 Investigators. Leighl NB, et al. Among authors: lorenzini p. J Clin Oncol. 2024 Oct 20;42(30):3593-3605. doi: 10.1200/JCO.24.01001. Epub 2024 Jun 10. J Clin Oncol. 2024. PMID: 38857463 Free PMC article. Clinical Trial.
Neuropsychological tests at the Italian Centers for Cognitive Disorders and Dementias: results from a survey on 450 specialized services.
Vaccaro R, Lorenzini P, Giaquinto F, Matascioli F, Carnevale G, Sciancalepore F, Gasparini M, Salvi E, Corbo M, Locuratolo N, Vanacore N, Bacigalupo I; Permanent Table of the National Dementia Plan Study Group; CCDDs Study Group. Vaccaro R, et al. Among authors: lorenzini p. Aging Clin Exp Res. 2024 Dec 20;37(1):1. doi: 10.1007/s40520-024-02869-6. Aging Clin Exp Res. 2024. PMID: 39704981 Free PMC article.
Impact of switching from EFV/F/TDF to B/F/TAF on psychiatric symptoms and neurocognition.
Vergori A, Del Duca G, Lorenzini P, Brita AC, Mastrorosa I, Fusto M, Camici M, Ottou S, Gagliardini R, Paulicelli J, De Zottis F, Grilli E, Esvan R, Plazzi MM, Mazzotta V, Bellagamba R, Antinori A, Pinnetti C. Vergori A, et al. Among authors: lorenzini p. AIDS. 2024 Oct 25. doi: 10.1097/QAD.0000000000004043. Online ahead of print. AIDS. 2024. PMID: 39453875
A multicomponent personalized prevention program in the primary care setting: a randomized clinical trial in older people with noncommunicable chronic diseases (Primacare_P3 study).
Pilotto A, Barbagelata M, Lacorte E, Custodero C, Veronese N, Maione V, Morganti W, Seminerio E, Piscopo P, Fabrizi E, Lorenzini P, Carbone E, Lora Aprile P, Solfrizzi V, Barbagallo M, Vanacore N; PrimaCare_P3 study group. Pilotto A, et al. Among authors: lorenzini p. Trials. 2024 Sep 13;25(1):611. doi: 10.1186/s13063-024-08413-1. Trials. 2024. PMID: 39272196 Free PMC article. Clinical Trial.
The Profile of the Italian Centers for Cognitive Disorders and Dementia in the Context of New Drugs in Alzheimer's Disease.
Giaquinto F, Lorenzini P, Salvi E, Carnevale G, Vaccaro R, Matascioli F, Corbo M, Locuratolo N, Vanacore N, Bacigalupo I; National Dementia Plan Study Group; CCDDs Study Group. Giaquinto F, et al. Among authors: lorenzini p. J Alzheimers Dis. 2024;101(2):509-524. doi: 10.3233/JAD-240594. J Alzheimers Dis. 2024. PMID: 39213073 Free PMC article.
Development of a prediction model of conversion to Alzheimer's disease in people with mild cognitive impairment: the statistical analysis plan of the INTERCEPTOR project.
Lombardo FL, Lorenzini P, Mayer F, Massari M, Piscopo P, Bacigalupo I, Ancidoni A, Sciancalepore F, Locuratolo N, Remoli G, Salemme S, Cappa S, Perani D, Spadin P, Tagliavini F, Redolfi A, Cotelli M, Marra C, Caraglia N, Vecchio F, Miraglia F, Rossini PM, Vanacore N; INTERCEPTOR Network. Lombardo FL, et al. Among authors: lorenzini p. Diagn Progn Res. 2024 Jul 25;8(1):11. doi: 10.1186/s41512-024-00172-6. Diagn Progn Res. 2024. PMID: 39049042 Free PMC article.
233 results